Product

PerioChip®

Atridox™

Arestin™

Periostat™

Company

Dexcel Pharma Inc. 866-PERIOCHIP (866-737-4624)

Block Drug Corp. 800-OK-BLOCK (800-652-5625)

OraPharma Inc. 866-ARESTIN

CollaGenex Pharmaceuticals 888-339-5678

Active
ingredient

2.5 mg chlorhexidine gluconate

10% doxycycline hyclate

1 mg resorbable minocycline microspheres

20 mg doxycycline hyclate

Indications

PerioChip is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. PerioChip may be used as part of a periodontal maintenance program, which includes good oral hygiene and scaling and root planing.

Atridox is indicated for for use in the treatment of chronic adult periodontitis for a gain in clinical attachment, reduction in probing depth, and reduction in bleeding on probing.

Adjunctive treatment for adult periodontal disease used in conjunction with scaling and root planing.

Periostat is indicated for use as an adjunct to scaling and root planing to promote attachment level gains and to reduce pocket depth in patients with adult periodontitis.

Delivery

Subgingivally placed 4 mm x 5 mm x 0.35 mm bioabsorbable sustained release chip. Easily inserts within one minute. Dissolves in 7-10 days. Restrict interdental care in treated area.

Controlled/sustained release gel for subgingival application. Hardens to a wax-like consistency upon subgingival application; 14-day release. Restrict interdental care in treated area.

Powder substance placed subgingivally; 14-day release

Oral capsule, 20 mg twice a day (BID). No restriction on oral hygiene care.

Clinical
outcome

Results showed improvement in secondary outcome variables over SRP alone.

Results were equal to SRP with secondary AND primary outcome variables achieved.

Clinical data online at arestin.com

Results showed improvement over SRP group, including secondary and primary outcome variables achieved.

Additional
information

Results were based upon baseline SRP and placement of the chip, followed by placement of additional chips and three and six months with supragingival instrumentation at sites that were 5 mm or greater.

Mono-therapy based research against SRP. The only ADA sealed product for use in the arrest of periodontitis.

Available April 2, 2001. Received FDA approval in February, 2001.

Oral enzyme suppresser. Research based upon baseline SRP and Periostat taken twice a day with clinical perimeters measured at three, six, and nine months. No additional instrumentation was performed at those intervals.